• Source: List of investigational antipsychotics

This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in December 2017. It is likely to become outdated with time.




Receptor modulators






= Monoamine receptor modulators

=
Brilaroxazine (RP5063; oxaripiprazole) – atypical antipsychotic (D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist)
FKF-02SC (TGOF-02N) – atypical antipsychotic (D2 and 5-HT2A receptor antagonist, other actions)
Masupirdine (SUVN-502) – 5-HT6 receptor antagonist
N-Methylamisulpride (LB-102) – D2,3, 5-HT7, receptor antagonist (methylated version of amisulpride)
Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist
Ulotaront (SEP-856, SEP-363856) – 5-HT1A receptor and TAAR1 agonist
Usmarapride (SUVN-D4010) – 5-HT4 receptor partial agonist




= Glutamate receptor modulators

=
Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR2 and mGluR3 agonist
Iclepertin – glycine transporter-1 inhibitor




= Acetylcholine receptor modulators

=
Emraclidine (CVL-231) – M4 muscarinic acetylcholine receptor positive allosteric modulator.
ML-007 – M1 and M4 muscarinic acetylcholine receptor agonist.
NBI-1117568 (HTL 0016878) – M4 muscarinic acetylcholine receptor agonist.
NS-136 – M4 muscarinic acetylcholine receptor positive allosteric modulator




= Cannabinoid receptor modulators

=
Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions




= Other/mixed receptor modulators

=
CVN766 – Orexin receptor type 1 antagonist
Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions
Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT2A and σ2 receptor antagonist
TAK-041 (NBI 1065846) – GPR139 receptor agonist




Enzyme inhibitors


Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor. (DAAO is a pathway to NMDAR.)
MK-8189 – phosphodiesterase 10A inhibitor.
Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor
Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor




Ion channel modulators


Evenamide (NW-3509; NW-3509A) – Nav1.3, Nav1.7, and Nav1.8 voltage-gated sodium channel blocker




Others


TS-134 (TS-1341) – undefined mechanism of action
Kratom – Has shown antipsychotic-like effects on par with haloperidol in animal testing




See also


List of investigational drugs




References






External links


AdisInsight – Springer
2016 Medicines in Development for Mental Health – PhRMA

Kata Kunci Pencarian:

• List of investigational antipsychotics
• Lists of drugs
• Lists of investigational drugs
• Antipsychotic
• List of investigational antidepressants
• List of antidepressants
• Sodium benzoate
• Atypical antipsychotic
• List of investigational anxiolytics
• Pyridoxamine